Tavaborole is an antifungal agent used to treat onychomycosis, a fungal infection of the nail. Tavaborole functions by inhibiting Leucyl-tRNA synthetase, or LeuRS, an essential fungal enzyme required for protein synthesis and for the catalysis of ATP-dependent ligation of L-leucine to tRNA(Leu).
- Mechanism
- Curator reviewed
Tavaborole exerts its antifungal activity by blocking cellular protein synthesis through the formation of an adduct with cytoplasmic leucyl-aminoacyl transfer RNA (tRNA) synthetase.
- Primary indication
- Indicated for the treatment of onychomycosis (a fungal infection) of the toenails due to Trichophyton rubrum or Trichophyton mentagrophytes.Curator reviewed · 2 structured indications
- Formula / weight
- C7H6BFO2 · 151.93 g/mol (avg)
- First approval
- United States, 2014
- Code names
- AN-2690
- Brand names
Resolves to
Clinical / RWD
Structure
InChIKey
LFQDNHWZDQTITF-UHFFFAOYSA-NSMILESOB1OCC2=CC(F)=CC=C12What you can answer from here — as of March 06, 2025
1Protein targetEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with Tavaborole, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account